Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Timothy Eugene Sullivan net worth and biography

Timothy Sullivan Biography and Net Worth

CFO of Apellis Pharmaceuticals

Tim has served as our chief financial officer since October 2017. From January 2014 to October 2017, Tim served as partner at Aju IB Investment, a venture capital firm, at which he led the firm’s investments in life sciences companies. Prior to joining Aju IB Investment, from December 2011 to January 2014, Tim was managing director, head of life sciences investment banking at RBS Citizens. Tim was an observer on our board of directors from November 2014 until October 2017. Tim has previously served as a director of G1 Therapeutics, Inc. and Molecular Templates, Inc. Tim received his MBA degree from the Columbia Business School and his BA degree in biology from Harvard University.

What is Timothy Eugene Sullivan's net worth?: The estimated net worth of Timothy Eugene Sullivan is at least $4.65 million as of April 1st, 2024. Mr. Sullivan owns 93,338 shares of Apellis Pharmaceuticals stock worth more than $4,653,833 as of April 27th. This net worth approximation does not reflect any other assets that Mr. Sullivan may own. Additionally, Mr. Sullivan receives a salary of $716,410.00 as CFO at Apellis Pharmaceuticals. Learn More about Timothy Eugene Sullivan's net worth.
How old is Timothy Eugene Sullivan?: Mr. Sullivan is currently 53 years old. There are 7 older executives and no younger executives at Apellis Pharmaceuticals. The oldest executive at Apellis Pharmaceuticals is Mr. James G. Chopas CPA, VP, Corporate Controller & Chief Accounting Officer, who is 57 years old. Learn More on Timothy Eugene Sullivan's age.
What is Timothy Eugene Sullivan's salary?: As the CFO of Apellis Pharmaceuticals, Inc., Mr. Sullivan earns $716,410.00 per year. The highest earning executive at Apellis Pharmaceuticals is Dr. Cedric Francois M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,200,000.00 per year. Learn More on Timothy Eugene Sullivan's salary.
How do I contact Timothy Eugene Sullivan?: The corporate mailing address for Mr. Sullivan and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Timothy Eugene Sullivan's contact information.
Has Timothy Eugene Sullivan been buying or selling shares of Apellis Pharmaceuticals?: Over the course of the past ninety days, Timothy Eugene Sullivan has sold $234,640.00 in Apellis Pharmaceuticals stock. Most recently, Timothy Eugene Sullivan sold 4,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $58.66, for a transaction totalling $234,640.00. Following the completion of the sale, the chief financial officer now directly owns 93,338 shares of the company's stock, valued at $5,475,207.08. Learn More on Timothy Eugene Sullivan's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 55 times. They sold a total of 832,985 shares worth more than $51,199,751.25. The most recent insider tranaction occured on April, 8th when insider Pascal Deschatelets sold 69,107 shares worth more than $3,743,526.19. Insiders at Apellis Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 4/8/2024.

Timothy Eugene Sullivan Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2024	Sell	4,000	$58.66	$234,640.00	93,338
3/1/2024	Sell	6,000	$63.22	$379,320.00	93,338
2/12/2024	Sell	1,431	$67.77	$96,978.87	93,338
1/22/2024	Sell	3,551	$65.00	$230,815.00	95,675
1/16/2024	Sell	2,235	$66.81	$149,320.35	99,226
7/3/2023	Sell	6,779	$89.97	$609,906.63	77,713
6/5/2023	Sell	69,779	$88.80	$6,196,375.20	77,713
8/29/2019	Buy	11,699	$29.71	$347,577.29	11,699

Timothy Eugene Sullivan Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $49.86

$48.85

$50.98

50 Day Range

MA: $57.84

$47.51

$71.73

2 Week Range

Now: $49.86

$19.83

$94.75

Volume

1,215,021 shs

Average Volume

1,146,601 shs

Market Capitalization

$6.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

Timothy Sullivan Biography and Net Worth

What is Timothy Eugene Sullivan's net worth?

How old is Timothy Eugene Sullivan?

What is Timothy Eugene Sullivan's salary?

How do I contact Timothy Eugene Sullivan?

Has Timothy Eugene Sullivan been buying or selling shares of Apellis Pharmaceuticals?

Who are Apellis Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Apellis Pharmaceuticals?